Effectiveness of Telemedicine Prescribing and a Long‐Acting Obesity Medication Behavioral Program: A 24‐Week Single‐Arm Study
Obesity · 2025
DOI: 10.1002/oby.70056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, 2025. Verfasst von Leslie J Heinberg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychology, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Obesity, Anti-Obesity Agents, Behavior Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: WW International.
Abstract (Originalsprache)
Objective
Limited data exist on telemedicine prescribing of semaglutide and tirzepatide. The effects of a telehealth obesity management program combining the provision of semaglutide and tirzepatide with a behavioral program tailored for long‐acting antiobesity medications (AOMs) were evaluated.
Methods
In this single‐arm study, 180 participants recruited from a telehealth medical obesity program received a virtual behavioral program tailored for long‐acting AOMs, Bluetooth wireless scales, and a blood pressure (BP) cuff. Participants' (mean age = 44.1; 91% female; 81% White; mean weight = 102.8 kg) weight, BP, eating habits, dietary quality, physical activity, and side effects were assessed at baseline and at 12 and 24 weeks. Wilcoxon rank sum tests were conducted, and p values were adjusted using a false discovery rate approach. Intent‐to‐treat analysis was performed using last observation carried forward (LOCF).
Results
Weight loss was 7.2% (SD = 5.2%) at 12 weeks and 12.3% (SD = 6.9%) at 24 weeks ( p < 0.0001). Mean BP declined from 131.0/83.8 (SD = 17.2/12.2) to 122.5/78.7 (SD = 13.7/10.1) at 12 weeks and 120.0/78.2 (SD = 13.5/10.6) at 24 weeks ( p < 0.0001). Participants significantly improved their eating habits, diet quality, and activity. Side effects were markedly lower than in previously reported trials.
Conclusions
Virtually delivered treatment combining telemedicine and a behavioral program tailored for long‐acting AOMs demonstrated clinically significant improvements in weight, BP, diet, and activity over 24 weeks. Trial Registration ClinicalTrials.gov identifier: NCT06034457
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Psychology, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.
- WW International Inc., New York City, New York, USA.
- Weight and Eating Disorders Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Psychiatry and Psychology, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Quantitative Health Sciences and Center for Quantitative Metabolic Research, Cleveland Clinic Research, Cleveland, Ohio, USA.
- Department of Health Outcomes & Biomedical Informatics, University of Florida College of Medicine, Gainesville, Florida, USA.
ORCID-Profile: Leslie J Heinberg, Gary D Foster
Förderung
- WW International
Zitieren
APA
Heinberg, L. J., Lee, A. M., Foster, G. D., DiVita, A., Allman, M., Rotroff, D., Dargham, C. B., & Cardel, M. I. (2025). Effectiveness of Telemedicine Prescribing and a Long‐Acting Obesity Medication Behavioral Program: A 24‐Week Single‐Arm Study. Obesity. https://doi.org/10.1002/oby.70056
Vancouver
Heinberg LJ, Lee AM, Foster GD, DiVita A, Allman M, Rotroff D, et al. Effectiveness of Telemedicine Prescribing and a Long‐Acting Obesity Medication Behavioral Program: A 24‐Week Single‐Arm Study. Obesity. 2025. doi:10.1002/oby.70056
BibTeX
@article{Heinberg2025,
author = {Heinberg, Leslie J and Lee, Alexandra M and Foster, Gary D and DiVita, Amy and Allman, Matthew and Rotroff, Daniel and Dargham, Carla Bou and Cardel, Michelle I},
title = {Effectiveness of Telemedicine Prescribing and a Long‐Acting Obesity Medication Behavioral Program: A 24‐Week Single‐Arm Study},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.70056}
}
EUVIMED